Hbk Investments L P Macrogenics Inc Transaction History

Hbk Investments L P

4 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2019 May 15, 2019	BUY	$11.11 - $25.6 $1.9 Million - $4.38 Million	171,043 Added 730.98%	194,442 $3.5 Million
Q4 2018 Feb 14, 2019	SELL	$11.75 - $21.42 $115,161 - $209,937	-9,801 Reduced 29.52%	23,399 $297,000
Q3 2018 Nov 14, 2018	SELL	$19.26 - $23.46 $208,008 - $253,368	-10,800 Reduced 24.55%	33,200 $712,000
Q2 2018 Aug 14, 2018	BUY	$19.78 - $24.67 $870,320 - $1.09 Million	44,000 New	44,000 $909,000

132

55.4M

215K

238K

Ticker MGNX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 61,458,800
Market Cap $199M
Description
MacroGenics, Inc., a biopharmaceutical company, develops and commercializes antibody-based therapeutics to treat cancer in the United States. Its approved product is MARGENZA (margetuximab-cmkb), a human epidermal growth factor receptor 2 (HER2) receptor antagonist indicated, in combination with chemotherapy, for the treatment of adult patients ...

Get notified when there are updates to the investment portfolio of Hbk Investments L P, based on Form 13F filings with the SEC.

Stay updated on Hbk Investments L P with notifications on news.